New research published in the New England Journal of Medicine found that a combination of the monoclonal antibodies casirivimab and imdevimab, REGEN-COV, significantly reduced the risk of COVID-19–related hospitalizations and death in patients. The study results were part of the phase 3 portion of an adaptive trial.